HVAX Technologies is a specialized, high-growth engineering firm providing **turnkey cleanroom and controlled environment infrastructure**. Established in **2010** and recently listed on the **NSE Emerge** platform (**October 2024**), the company operates an **asset-light, integrated model** that manages the entire project lifecycle—from conceptual design and feasibility studies to installation, validation, and commissioning. --- ### **The "Single Source Engineering" Platform** HVAX differentiates itself through a unified framework that eliminates the need for multiple contractors. By managing the transition from **Lead Generation → Design → Execution → Handover**, the company typically achieves an average project timeline of **120 days**. **Core Service Portfolio:** * **Turnkey Cleanroom Projects:** Design and construction of contamination-controlled environments. * **HVAC & Utilities:** Specialized heating, ventilation, and air conditioning systems, including Air Handling Units (AHUs) and utility distribution tailored for regulatory compliance. * **Modular Infrastructure:** Supply of prefabricated partitions, ceilings, lab furniture, and cleanroom accessories. * **Electrical & Automation:** Integration of **HT/LT panels** and Building Management Systems (**BMS**). * **Validation & Compliance:** Ensuring facilities meet stringent global standards, including **USFDA, EU-GMP (Grades A-D), WHO-GMP, and ISO 14644-1**. --- ### **Operational Footprint & Global Reach** While headquartered in India, HVAX has established a significant international footprint, particularly in emerging markets where pharmaceutical manufacturing is expanding rapidly. | Metric | Details | | :--- | :--- | | **Project Experience** | **250+ projects** completed across **22+ countries** | | **Workforce** | **135+ professionals** (as of FY25) | | **Client Retention** | Approximately **50% repeat client rate** | | **Key Geographies** | India, Africa (Kenya, Ghana, Uganda, Nigeria, Algeria), Middle East (Iraq), and South Asia (Nepal, Sri Lanka) | **High-Value International Projects:** * **JM Addo (Ghana):** Formulation Facility – **₹45 Cr** * **Me Cure (Nigeria):** Oral Solid Dosage Facility – **₹32 Cr** * **Letap Pharmaceuticals (Ghana):** OSD Plant & Warehouses – **$5 Million** * **Sands Active (Sri Lanka):** Multi-Dosage Plant – **$3 Million** * **Biopharma (Kenya):** OSD, Ointment & Liquid – **₹16 Cr** --- ### **Strategic Pivot: Sector Diversification & Market Expansion** Historically, HVAX has been heavily reliant on the **Pharmaceutical & Biotech** sector (approx. **95%** of revenue). Management is currently executing a transition into a multi-sector infrastructure specialist to mitigate sectoral concentration risk. * **Hospital & Healthcare:** A primary focus for **FY26**, moving into integrated hospital labs and surgical environments. * **Semiconductors & Electronics:** Secured an initial solar project worth **₹3 Cr**; targeting cleanroom-compliant infrastructure for high-precision electronics. * **Data Centers:** Positioning as a turnkey partner for energy-intensive, AI-led infrastructure requiring specialized cooling. * **Inorganic Growth:** Finalizing the acquisition of a majority stake in **Krew Instruments Private Limited** (approx. **₹1.40 Cr**) to unlock synergies in bespoke pharma solutions. * **New Geographies:** Actively evaluating entry into **Latin America (LATAM)** and the **GCC** region. --- ### **Technological Edge: Smart Cleanrooms & AI** HVAX is embedding advanced technology to maintain a competitive advantage and ensure "zero downtime" for mission-critical infrastructure. * **IoT Integration:** Real-time **24/7 monitoring** of particle counts, pressure, and humidity via mobile dashboards. * **Predictive Maintenance:** An **IoT-based Alert Program** provides notifications for maintenance, preventing unscheduled shutdowns. * **Sterilization Innovation:** Development of **Far-UVC (UV222)** technology for continuous, human-safe sterilization. * **Modular Scalability:** Utilizing lightweight, durable materials to accelerate delivery cycles and allow for future facility expansion. --- ### **Financial Performance & Capital Structure** The company has demonstrated consistent growth in revenue and profitability, supported by its successful **₹33.53 Cr IPO** in late 2024. **Comparative Financial Summary:** | Particulars (₹ Cr) | H1 FY26 (Unaudited) | FY25 (Audited) | FY24 (Audited) | | :--- | :--- | :--- | :--- | | **Total Income** | **62.79** | **131.42** | **107.47** | | **EBITDA** | **8.53** | **18.97** | **14.42** | | **EBITDA Margin (%)** | **13.58%** | **14.44%** | **13.42%** | | **Net Profit (PAT)** | **4.92** | **11.04** | **8.51** | | **Net Worth** | **-** | **72.02** | **-** | **Key Financial Highlights:** * **Growth Visibility:** Management has guided for a **35% to 50% CAGR** over the next few years. As of March 2026, the **Active Project Pipeline** stands at **₹719.26 Cr**, with a current **Order Book of ₹342.63 Cr**. * **Efficiency:** **Fixed Asset Turnover** improved to **16.89x** in FY25, reflecting the efficiency of the asset-light model. * **Liquidity:** The **Current Ratio** stands at a healthy **2.44x**, with **Cash & Bank Balances** increasing to **₹14.27 Cr** post-IPO. * **Leverage:** The **Debt-to-Equity Ratio** improved from **0.79** (FY24) to **0.39** (FY25). * **Shareholder Returns:** The company executed a **2:1 Bonus Issue** in April 2024. --- ### **Risk Profile & Mitigation** | Risk Factor | Impact | Mitigation Strategy | | :--- | :--- | :--- | | **Sector Concentration** | High dependency on Pharma cycles. | Aggressive diversification into **Semiconductors, Data Centers, and Healthcare**. | | **Human Capital** | Skilled manpower is the primary bottleneck for scaling. | Investing in internal leadership development and specialized engineering training. | | **Execution Risk** | Potential for cost overruns in 120-day cycles. | Disciplined working capital management and use of **IPO proceeds** for liquidity. | | **Regulatory Shifts** | Changes in USFDA or EU-GMP standards. | In-house compliance team ensures all designs are **audit-ready** and meet **ISO 14644** standards. | ### **Investment Outlook** HVAX Technologies is transitioning from a "launching pad" phase to large-scale project execution. With a robust pipeline exceeding **₹700 Cr**, a debt-light balance sheet, and a strategic pivot toward high-growth tech sectors like semiconductors and data centers, the company is positioned as a high-alpha play in the specialized industrial infrastructure space.